| Literature DB >> 32273535 |
Ana Paula Del Vesco1,2, Michael G Kaiser1, Melissa S Monson1, Huaijun Zhou3, Susan J Lamont4.
Abstract
Newcastle disease virus (NDV) replication depends on the translation machinery of the host cell; therefore, the eukaryotic translation initiation factor 2 (eIF2) gene family is a likely candidate for control of viral replication. We hypothesized that differential expression of host genes related to translation and innate immune response could contribute to differential resistance to NDV in inbred Fayoumi and Leghorn lines. The expression of twenty-one genes related to the interferon signaling pathway and the eIF2 family was evaluated at two- and six-days post infection (dpi) in the spleen from both lines, either challenged by NDV or nonchallenged. Higher expression of OASL in NDV challenged versus nonchallenged spleen was observed in Leghorns at 2 dpi. Lower expression of EIF2B5 was found in NDV challenged than nonchallenged Fayoumis and Leghorns at 2 dpi. At 2 dpi, NDV challenged Fayoumis had lower expression of EIF2B5 and EIF2S3 than NDV challenged Leghorns. At 6 dpi, NDV challenged Fayoumis had lower expression of EIF2S3 and EIF2B4 than NDV challenged Leghorns. The genetic line differences in expression of eIF2-related genes may contribute to their differential resistance to NDV and also to understanding the interaction between protein synthesis shut-off and virus control in chickens.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32273535 PMCID: PMC7145804 DOI: 10.1038/s41598-020-63074-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Gene expression in the spleen of Fayoumi and Leghorn chickens NDV challenged or nonchallenged at 2 and 6-days post infection (dpi).
| Major category | 2 dpi | 6 dpi | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fayoumi | Leghorn | Fayoumi | Leghorn | |||||||||
| NDV2 | Non3 | NDV2 | Non3 | NDV2 | Non3 | NDV2 | Non3 | |||||
| Receptors | 18.83 ± 0.3 | 18.81 ± 0.5 | 18.23 ± 0.3 | 19.09 ± 0.5 | 17.75 ± 0.8 | 18.55 ± 0.8 | 19.26 ± 0.7 | 19.09 ± 0.8 | ||||
| 16.59 ± 0.6 | 16.01 ± 0.6 | 15.65 ± 0.6 | 15.83 ± 0.6 | 14.94 ± 0.6 | 16.06 ± 0.6 | 16.14 ± 0.5 | 15.46 ± 0.6 | |||||
| Cytokines | 21.16 ± 0.7 | 20.66 ± 0.8 | 19.07 ± 0.5 | 20.15 ± 0.8 | 19.47 ± 1.0 | 20.03 ± 1.0 | 21.18 ± 0.5 | 20.63 ± 1.0 | ||||
| 15.06 ± 0.6 | 14.87 ± 0.7 | 12.93 ± 0.6† | 14.01 ± 0.7 | 13.66 ± 0.7 | 14.88 ± 0.7 | 15.46 ± 0.6† | 15.00 ± 0.7 | |||||
| 13.80 ± 0.5 | 13.95 ± 0.6 | 13.70 ± 0.5 | 14.17 ± 0.6 | 12.81 ± 0.8 | 14.87 ± 0.8 | 15.42 ± 0.7 | 14.16 ± 0.8 | |||||
| 12.48 ± 0.4 | 11.88 ± 0.5 | 12.10 ± 0.4 | 11.94 ± 0.5 | 11.51 ± 0.2 | 12.76 ± 0.2 | 13.21 ± 0.6 | 12.27 ± 0.7 | |||||
| 12.15 ± 0.15 | 12.60 ± 0.6 | 12.10 ± 0.5 | 12.52 ± 0.6 | 10.76 ± 0.6 | 11.56 ± 0.6 | 12.66 ± 0.5 | 12.04 ± 0.6 | |||||
| Signaling molecules | 18.94 ± 0.4† | 18.68 ± 0.5 | 18.32 ± 0.4 | 18.85 ± 0.5† | 17.49 ± 0.5 A† | 18.72 ± 0.5 A | 19.09 ± 0.4Ba | 17.15 ± 0.5Bb† | ||||
| 13.78 ± 0.3 | 13.78 ± 0.4 | 13.91 ± 0.3 | 13.70 ± 0.4 | 12.27 ± 0.5 | 13.09 ± 0.5 | 13.65 ± 0.4 | 13.75 ± 0.5 | |||||
| 16.35 ± 0.6 | 16.31 ± 0.7 | 15.84 ± 0.6 | 16.01 ± 0.7 | 15.22 ± 0.5 | 15.95 ± 0.5 | 16.87 ± 0.4 | 15.79 ± 0.5 | |||||
| ISG1 | 16.56 ± 0.4† | 15.17 ± 0.4 | 17.30 ± 0.4a | 15.59 ± 0.4b | 14.81 ± 0.5† | 15.03 ± 0.5 | 15.89 ± 0.4 | 14.51 ± 0.5 | ||||
| eIF2 family | 17.44 ± 0.4 | 17.05 ± 0.4 | 17.61 ± 0.4 | 17.15 ± 0.4 | 16.47 ± 0.4 | 16.14 ± 0.4 | 17.08 ± 0.3 | 16.81 ± 0.4 | ||||
| 12.65 ± 0.4 | 12.56 ± 0.4 | 12.37 ± 0.3 | 12.41 ± 0.4 | 11.70 ± 0.3 | 12.08 ± 0.3 | 13.00 ± 0.2 | 12.76 ± 0.3 | |||||
| 17.60 ± 0.3 | 18.19 ± 0.2 | 18.14 ± 0.3 | 17.45 ± 0.2 | 16.80 ± 0.5 | 17.43 ± 0.4 | 18.83 ± 0.4 | 18.46 ± 1.1 | |||||
| 18.98 ± 0.4 | 20.19 ± 0.4 | 19.77 ± 0.4 | 19.00 ± 0.4 | 18.59 ± 0.7 | 19.42 ± 0.4 | 20.65 ± 0.6 | 19.70 ± 0.7 | |||||
| 14.37 ± 0.3 | 14.77 ± 0.4 | 18.60 ± 0.3 | 18.80 ± 0.4 | 13.58 ± 0.3 | 14.32 ± 0.3 | 18.87 ± 0.3 | 19.08 ± 0.5 | |||||
| 13.11 ± 0.4 | 13.68 ± 0.4 | 13.10 ± 0.3 | 12.71 ± 0.4 | 12.86 ± 0.6 | 13.02 ± 0.4 | 13.77 ± 0.6 | 13.30 ± 0.4 | |||||
| 17.62 ± 0.4 | 17.64 ± 0.5 | 16.92 ± 0.4 | 17.11 ± 0.4 | 17.09 ± 0.3 | 17.05 ± 0.4 | 17.33 ± 0.3 | 17.48 ± 0.4 | |||||
| 14.93 ± 0.4 | 14.72 ± 0.6 | 14.16 ± 0.4 | 14.34 ± 0.3 | 13.91 ± 0.3 | 14.29 ± 0.4 | 14.77 ± 0.3 | 14.68 ± 0.5 | |||||
| 12.08 ± 0.4 | 11.79 ± 0.5 | 11.27 ± 0.4 | 11.05 ± 0.4 | 10.25 ± 0.3 A | 11.06 ± 0.3 | 11.80 ± 0.3B | 11.61 ± 0.2 | |||||
| 10.11 ± 0.4 | 12.46 ± 0.7A | 12.11 ± 0.4 | 10.81 ± 0.7Bb | 10.82 ± 0.3a | 12.35 ± 0.3Ab | 10.45 ± 0.3 | 10.72 ± 0.6B | |||||
Pairwise comparisons between groups were based on a linear model and tested effects of line, challenge status, dpi. Significant line differences are shown as bold capitalized letters (FDR < 0.05) and trends as capitalized letters (FDR < 0.1). Significant differences due to challenge status are indicated by bold small letters (FDR < 0.05) and trends by small letters (FDR < 0.1). Significant differences across dpi are illustrated with *(FDR < 0.05) and trends with †(FDR < 0.1).
1ISG, Interferon stimulated genes. 2NDV, NDV challenged. 3Non, nonchallenged.
Figure 1NDV challenge effect on the expression of (a,b) cytokines, (c,d) receptors and signaling molecules, and (e,f) eIF2 family-related genes in the spleen of chickens at 2- and 6-days post infection (dpi). The bars represent the fold change between the NDV challenged and nonchallenged within genetic line: Fayoumis (black bars) and Leghorns (red bars). *FDR < 0.1, **FDR < 0.05.
Figure 2Genetic line effect on the expression of (a,b) cytokines, and (c,d) receptors and signaling molecules in the spleens of chickens at 2- and 6-days post infection (dpi). The bars represent the fold change between the Fayoumis and the Leghorns within treatment: NDV challenged (black bars) or nonchallenged chickens (red bars). *FDR < 0.1.
Figure 3Genetic line effect on the expression of (a,b) eIF2 family-related genes and EIF2S3 gene (c,d) in the spleen of chickens at 2 and 6-days post infection (dpi). The bars represent the fold change between the Fayoumis and the Leghorns within NDV challenged (black) and nonchallenged chickens (red bars). *FDR < 0.1, **FDR < 0.05, ***FDR < 0.001.
Figure 4Heat map showing the fold change between 6- and 2-days post infection within line and challenge status in the spleen. See Table 1 and Supplementary Table S1 for significance.
Primer sequences used for quantitative real-time PCR.
| Gene | Sequence (5′-3′) | NCBI access number/ Reference | |
|---|---|---|---|
| Forward primer | Reverse primer | ||
| CGGAAAATGGTACATCATGC | AAAGTTTTGGGAAACCAACG | See reference[ | |
| TCAGGTTCGAAAAATGTGGCT | GGTAGTCTCTGGAGCAAGATCA | XM_015299270.2 | |
| GACAGCCAACGCCAAAGC | GTCGCTGCTGTCCAAGCATT | See reference[ | |
| CTGGATTGACCGCACACGCCA | GGGAGCGCGTGCCTTGGTTTA | See reference[ | |
| GCTCTACATGTCGTGTGTGATGAG | TGTCGATGTCCCGCATGA | See reference[ | |
| GCT CGC CGG CTT CGA | GGTAGGTCTGAAAGGCGAACAG | See reference[ | |
| CGCTCAGAACGACGTCAA | GTCGTCCACACCAACGAG | See reference[ | |
| AGAGGCTGAGGGGTACGG | ATCTTCACGCTCTCCAAGGG | XM_015290965.2 | |
| CGTCCGTGCGGGTATTTCTG | AGCTGGTGAACTTGCTCCAA | XM_025152161.1 | |
| GTTCTCCAGCGACAAGGCTAA | CTCCATGCCAGAGAAGGCATC | NM_204880.2 | |
| GTCGACATCCTGCCTGCTTAC | GAAGCTGGGGGAGAAATCGC | XM_015293006.2 | |
| CGTCGACGTGGACATGAGAG | GCTGCAGCTTTTGCTTCCTT | XM_015283611.2 | |
| GTGGAGGACGATGTGACCG | AGGATCCAGGGCAGCAATTC | XM_420868.6 | |
| GACGTCTGACTCCACAAGCA | GTGGAACAGTTCAAGCCTGC | XM_025150723.1 | |
| CCTGGCATTTTTGTTGGCAGA | CCGACACGTATGACAGGTGA | NM_204597.1 | |
| CCGACCCGAATGTTACCGAT | TCGTGACCAGGACAATCCAC | NM_001006260.2 | |
| CAGGACCGAGGAGAGACCAT | GTATTCCAGCGAGGTGAGGC | XM_003642192.4 | |
| CTCCACGCCGCTCATTGTAT | AGTCAAACACAGGGCAGTGAA | XM_015287388.2 | |
| TGATCGGAAGTGATCAGAGGC | CTGTTCAGTGCCCACAATGAC | XM_015291004.2 | |
| CGCAGCCCCGCGTTA | AGCTCCGCTTTGCTTTTGC | XM_423512.6 | |
| GAGAAGCAGAGGAGAGGGGA | CATGGCCACATTTGCCATAGG | XM_015291568.2 | |
TLR7, toll-like receptors 7; IFNAR1, IFN-α receptor subunit 1; IFNA, interferon α multi-copy gene family; IFNB, interferon β; IL1B, interleukin 1β; IL6, interleukin 6; TNFA, tumor necrosis factor α; JAK1, janus kinase 1; STAT1, signal transducer and activator of transcription 1; ATF4, activating transcription factor 4; OASL, 2′-5′-oligoadenylate synthetase like; EIF2AK2, eukaryotic translation initiation factor 2 alpha kinase 2; EIF2AK3, eukaryotic translation initiation factor 2 alpha kinase 3; EIF2S1, eukaryotic translation initiation factor 2 subunit alpha; EIF2S2, eukaryotic translation initiation factor 2 subunit beta; EIF2S3, eukaryotic translation initiation factor 2 subunit gamma; EIF2B1, eukaryotic translation initiation factor 2B subunit alpha; EIF2B2, eukaryotic translation initiation factor 2B subunit beta; EIF2B3, eukaryotic translation initiation factor 2B subunit gamma; EIF2B4, eukaryotic translation initiation factor 2B subunit delta; EIF2B5, eukaryotic translation initiation factor 2B subunit epsilon.